Form 4 Moderna, Inc. For: Feb 12 Filed by: Bancel Stephane
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Barclays Downgrades Moderna (MRNA) to Equalweight
February 18, 2025 5:13 AM ESTBarclays analyst Gena Wang downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $45.00 (from $111.00).
The analyst comments "Key takeaways. Following MRNA pre-announcement (see note), 4Q24 financial updates were largely incremental, except disclosure of norovirus Ph3 NOVA-1 (NCT06592794) clinical hold... More
